Wave Life Sciences (WVE) Q1 2025 earnings summary

Executive summary

• Advanced clinical pipeline in obesity (INHBE/WVE-007), AATD (WVE-006), DMD (WVE-N531), and Huntington's disease (WVE-003), leveraging proprietary oligonucleotide chemistries and PRISM platform, with preclinical programs in liver, CNS, and lung.

• Completed dosing in initial INHBE/INLIGHT cohorts, advanced AATD multi-dose studies, and delivered positive 48-week DMD data supporting NDA filing in 2026.

• Engaged with FDA for accelerated approval in DMD and HD, with regulatory alignment on surrogate endpoints.

• No product revenue to date; operations funded by equity offerings, collaborations (notably GSK), and private placements.

• GSK collaboration is a key revenue source, with milestone and royalty potential; Takeda collaboration expired in October 2024.

Financial highlights

• Q1 2025 revenue was $9.2M, down from $12.5M year-over-year, reflecting lower GSK collaboration revenue and no Takeda revenue.

• R&D expenses rose to $40.6M (from $33.4M), driven by internal/external research and compensation.

• G&A expenses increased to $18.4M (from $13.5M), mainly due to share-based compensation and professional fees.

• Net loss widened to $46.9M from $31.6M year-over-year.

• Cash and equivalents at March 31, 2025 were $243.1M, expected to fund operations into 2027 (excluding future GSK milestones).

Outlook and guidance

• Initial INHBE/INLIGHT clinical data (safety, tolerability, weight loss, biomarkers) expected in H2 2025.

• Comprehensive AATD multi-dose and single-dose data from Restoration 2 anticipated in Q3 and fall 2025.

• NDA submission for DMD (N531) planned for 2026, with monthly dosing data included.

• IND submission for WVE-003 in Huntington's disease expected in H2 2025.

• New clinical programs from the discovery pipeline expected to enter clinic in 2026.